Role of chemotherapy in high grade urinary bladder tumour

Prospective study of outcomes following neoadjuvant chemotherapy (Gemcitabine and Cisplatin) in patients of muscle invasive urinary bladder cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2016/09/007241

Enrollment

Registered

2016-09-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- CARCINOMA BLADDER

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Performance Status (Eastern Cooperative Oncology Group - ECOG) 0 â?? 2 2. Histologically confirmed muscle-invasive bladder cancer 3. Resectable disease at diagnosis (clinical stages T2 - T4a, N0 - 1, M0) transitional cell carcinoma of the bladder 4. Patients should have adequate bone marrow function (white blood cell count > 3.0 x 109/L, platelet count > 150 x 109/L) 5. Renal function (serum creatinine

Exclusion criteria

Exclusion criteria: 1. No history of previous chemotherapy or radiotherapy. 2. Patients with previous history of other cancers

Design outcomes

Primary

Measure	Time frame
To evaluate the radiological and pathological response rateTimepoint: 6 MONTHS	—

Secondary

Measure	Time frame
1. Tolerability of the regimen 2.Intra-operative and post-operative outcome of definitive surgery (radical cystectomy) after GC regimen. Timepoint: 6 MONTHS	—

Countries

India

Contacts

Public ContactSUNNY GOEL

KING GEORGE MEDICAL UNIVERSITY

rahuljanaksinha@yahoo.co.in9554952051

Outcome results